Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway

被引:65
作者
Dong, Peixin [1 ]
Xu, Zhujie [2 ]
Jia, Nan [3 ]
Li, Dajin [1 ]
Feng, Youji [1 ]
机构
[1] Fudan Univ, Shanghai Med Coll, Hosp & Inst Obstet & Gynecol, Shanghai, Peoples R China
[2] Kanglian Hosp, Dept Cardiovasc Med, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 1, Dept Cardiol, Shanghai 200030, Peoples R China
关键词
GROWTH-FACTOR RECEPTOR; MUTANT; GENE; OVEREXPRESSION; SUPPRESSOR; RESISTANCE; CARCINOMA; MIGRATION; PROMOTER; BINDING;
D O I
10.1186/1476-4598-8-103
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: p53 is the most commonly mutated tumor suppressor gene in human cancers. In addition to the loss of tumor suppression function and exertion of dominant-negative effects over the remaining wild-type protein, several p53 mutants can gain novel oncogenic functions (gain-of-function, GOF) that actively regulate cancer development and progression. In human endometrial cancer, p53 mutation is more often associated with aggressive nonendometrioid cancer. However, it was unknown if p53 mutants contributed to endometrial cancer progression through the GOF properties. Methods: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA. Results: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway. Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway. Conclusion: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
引用
收藏
页数:7
相关论文
共 32 条
[21]  
Muller BF, 1996, ONCOGENE, V12, P1941
[22]   EGFR and cancer prognosis [J].
Nicholson, RI ;
Gee, JMW ;
Harper, ME .
EUROPEAN JOURNAL OF CANCER, 2001, 37 :S9-S15
[23]   Epidermal growth factor receptor (EGFR) signaling in cancer [J].
Normanno, N ;
De Luca, A ;
Bianco, C ;
Strizzi, L ;
Mancino, M ;
Maiello, MR ;
Carotenuto, A ;
De Feo, G ;
Caponigro, F ;
Salomon, DS .
GENE, 2006, 366 (01) :2-16
[24]   Cancer cells activate p53 in response to 10-formyltetrahydrofolate dehydrogenase expression [J].
Oleinik, NV ;
Krupenko, NI ;
Priest, DG ;
Krupenko, SA .
BIOCHEMICAL JOURNAL, 2005, 391 :503-511
[25]   THE EPIDEMIOLOGY OF ENDOMETRIAL CANCER [J].
PARAZZINI, F ;
LAVECCHIA, C ;
BOCCIOLONE, L ;
FRANCESCHI, S .
GYNECOLOGIC ONCOLOGY, 1991, 41 (01) :1-16
[26]   Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma [J].
Sakuragi, N ;
Hirai, A ;
Tada, M ;
Yamada, H ;
Yamamoto, R ;
Fujimoto, S ;
Moriuchi, T .
GYNECOLOGIC ONCOLOGY, 2001, 83 (03) :485-490
[27]  
Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO
[28]  
2-5
[29]   Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes [J].
Willis, A ;
Jung, EJ ;
Wakefield, T ;
Chen, XB .
ONCOGENE, 2004, 23 (13) :2330-2338
[30]  
YAGINUMA Y, 1991, CANCER RES, V51, P6506